Buscar
01/02/2025
Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features
Sierro-Martinez, B, Escamilla-Gomez, V, Perez-Ortega, L, Guijarro-Albaladejo, B, Hernandez-Diaz, P, de la Rosa-garrido, M, Lara-Chica, M, Rodriguez-Gil, A, Reguera-Ortega, JL, Sanoja-Flores, L, Arribas-Arribas, B, Montiel-Aguilera, MA, Carmona, G, Robles, MJ, Caballero-Velazquez, T, Briones, J, Einsele, H, Hudecek, M, Perez-Simon, JA, Garcia-Guerrero, E. Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features. CELLULAR ONCOLOGY. 2025; 48(1)DOI:10.1007/s13402-024-00984-0. PMID:39192092. IF:4.800(Q1/1D).
11/01/2025
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group
Oñate, G, Garrido, A, Arnan, M, Pomares, H, Alonso, E, Tormo, M, Diaz-Beya, M, Vives, S, Zamora, L, Sampol, A, Coll, R, Salamero, O, Cervera, M, Garcia, A, Vall-Llovera, F, Garcia-Avila, S, Bargay, J, Ortin, X, Iranzo, E, Guijarro, F, Pratcorona, M, Nomdedeu, JF, Esteve, J, Sierra, J. Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-024-01205-5. PMID:39799145. IF:11.600(Q1/1D).
07/01/2025
Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care
Salas, MQ, Solano, MT, González, MB, Gómez, MA, Fox, L, Artigas, MDP, Santamaría, A, González, MDQ, Salinas, AS, Camacho, JMS, Alvaro, VI, Abdallahi-Lefdil, Z, Navascues, JC, Pardo, L, Fernández-Luis, S, Suárez, LPV, Villar, S, Beorlegui-Murillo, P, Esquirol, A, García, II, González, SR, Mussetti, A, Lavilla, E, Lopez-Marín, J, Filaferro, S, Cedillo, A, Bento, L, Sureda, A. Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care. Frontiers in Immunology. 2025; 15DOI:10.3389/fimmu.2024.1512154. PMID:39840039. IF:5.900(Q1/2D).
01/01/2025
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials
González-Gil, C, Morgades, M, Lopes, T, Fuster-Tormo, F, Montesinos, P, Barba, P, Díaz-Beya, M, Hermosín, L, Maluquer, C, González-Campos, J, Bernal, T, Arriaga, MS, Zamora, L, Pratcorona, M, Martino, R, Larrayoz, MJ, Artola, T, Torrent, A, Vall-llovera, F, Tormo, M, Gil, C, Novo, A, Martínez-Sánchez, P, Ribera, J, Queipo, MP, González-Martínez, T, Cabrero, M, Cladera, A, Cervera, J, Orfao, A, Ribera, JM, Genescà, E. Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials. HAEMATOLOGICA. 2025; 110(1)DOI:10.3324/haematol.2024.285416. PMID:39113657. IF:10.100(Q1/2D).
01/01/2025
Alder-Reilly Leukocyte Inclusions in a patient with Mucopolysaccharidosis Type VII
Bhambi-Blanco, I, González-Alvarez, N, San-José, P. Alder-Reilly Leukocyte Inclusions in a patient with Mucopolysaccharidosis Type VII. ANNALES DE BIOLOGIE CLINIQUE. 2025; 83(-1)DOI:10.1684/abc.2025.1953. PMID:39953854. IF:0.400(Q4/10D).
01/01/2025
Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain
de Larrea, CF, Loscertales, J, Cabañas, V, Freiria, C, Blanchard, MJ, Askari, E, Perez, ML, Abril, L, Pardo, JL, Pinzón, S, Gálvez, JD, Amer, N, Páyer, AR, Sánchez, RG, Alcalá, MM, Capote, FJ, Moreno, D, Bolumburu, C, Rubio-Azpeitia, E, Sanz, RG. Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain. Therapeutic Advances in Hematology. 2025; 16DOI:10.1177/20406207251379670. PMID:. IF:3.100(Q2/4D).
21/11/2024
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
Döhner, H, Dinardo, CD, Appelbaum, FR, Craddock, C, Dombret, H, Ebert, BL, Fenaux, P, Godley, LA, Hasserjian, RP, Larson, RA, Levine, RL, Miyazaki, Y, Niederwieser, D, Ossenkoppele, G, Röllig, C, Sierra, J, Stein, EM, Tallman, MS, Tien, HF, Wang, JX, Wierzbowska, A, Wei, AH, Löwenberg, B. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. BLOOD. 2024; 144(21)DOI:10.1182/blood.2024025409. PMID:39133932. IF:23.100(Q1/1D).
12/11/2024
Cardiac events after allo-HCT in patients with acute myeloid leukemia
Salas, MQ, Cascos, E, López-García, A, Pérez, E, Baile-González, M, Rodríguez, CM, Cascón, MJP, Luque, M, Esquirol, A, Fernando, IH, Peña-Muñóz, F, Ormtegi, IO, Marín, AJS, Fernández-Luis, S, Dominguez-García, JJ, Fernández, SV, Girón, MFD, Pinedo, LG, Garcia, L, González-Rodriguez, AP, Torrado, T, Filaferro, S, Cedillo, A, Orti, G, Chacón, MJ. Cardiac events after allo-HCT in patients with acute myeloid leukemia. Blood Advances. 2024; 8(21)DOI:10.1182/bloodadvances.2024013535. PMID:39178345. IF:7.100(Q1/2D).